Company / Accounts Receivable
Ginkgo Bioworks Holdings, Inc. Accounts Receivable History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$24.0M
FY2025
5-year range
$17.2M / $131.5M
FY2021-FY2025
Trend
+9.9%
vs FY2024
Sector context
#90 of 115
Health Care
What the data says
Ginkgo Bioworks Holdings, Inc.'s accounts receivable of $24M is lower than 78% of companies in the Health Care sector (FY2025). Improved from $17M to $24M over the past 2 years.
Based on SEC 10-K filings.
$24M in FY2025 with a 5-year CAGR of +7.6%.
Improved from $17M to $24M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -33.3%
- 5-Year CAGR
- +7.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 22% in Health CareTop 78% of 115This company $24.0M Sector average $1.1B
▼
-97.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +7.6%, indicating consistent growth.
- In FY2025, accounts receivable increased 9.9% year-over-year.
- Ranks #90 out of 115 companies in the Health Care sector.
- Peak accounts receivable was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.79 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $24.0M | +9.9% |
| FY2024 | $21.9M | +27.4% |
| FY2023 | $17.2M | -78.8% |
| FY2022 | $80.9M | -38.5% |
| FY2021 | $131.5M | +688.0% |
| FY2020 | $16.7M | - |
| FY2019 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026